|
1
|
Mitchell PJ, Barker KT, Martindale JE,
Kamalati T, Lowe PN, Page MJ, Gusterson BA and Crompton MR: Cloning
and characterisation of cDNAs encoding a novel non-receptor
tyrosine kinase, brk, expressed in human breast tumours. Oncogene.
9:2383–2390. 1994.PubMed/NCBI
|
|
2
|
Lee H, Kim M, Lee KH, Kang KN and Lee ST:
Exon-intron structure of the human PTK6 gene demonstrates that PTK6
constitutes a distinct family of non-receptor tyrosine kinase. Mol
Cells. 8:401–407. 1998.PubMed/NCBI
|
|
3
|
Barker KT, Jackson LE and Crompton MR: BRK
tyrosine kinase expression in a high proportion of human breast
carcinomas. Oncogene. 15:799–805. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brauer PM and Tyner AL: Building a better
understanding of the intracellular tyrosine kinase PTK6-BRK by BRK.
Biochim Biophys Acta. 1806:66–73. 2010.PubMed/NCBI
|
|
5
|
Mizuguchi Y, Specht S, Isse K, Sasatomi E,
Lunz JG III, Takizawa T and Demetris AJ: Breast tumor
kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and
neoplastic biliary epithelia. J Hepatol. 63:399–407. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kamalati T, Jolin HE, Mitchell PJ, Barker
KT, Jackson LE, Dean CJ, Page MJ, Gusterson BA and Crompton MR:
Brk, a breast tumor-derived non-receptor protein-tyrosine kinase,
sensitizes mammary epithelial cells to epidermal growth factor. J
Biol Chem. 271:30956–30963. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen HY, Shen CH, Tsai YT, Lin FC, Huang
YP and Chen RH: Brk activates rac1 and promotes cell migration and
invasion by phosphorylating paxillin. Mol Cell Biol.
24:10558–10572. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ie Kim H and Lee ST: Oncogenic functions
of PTK6 are enhanced by its targeting to plasma membrane but
abolished by its targeting to nucleus. J Biochem. 146:133–139.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng M, Emmadi R, Wang Z, Wiley EL, Gann
PH, Khan SA, Banerji N, McDonald W, Asztalos S, Pham TN, et al:
PTK6/BRK is expressed in the normal mammary gland and activated at
the plasma membrane in breast tumors. Oncotarget. 5:6038–6048.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ostrander JH, Daniel AR and Lange CA:
Brk/PTK6 signaling in normal and cancer cell models. Curr Opin
Pharmacol. 10:662–669. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goel RK and Lukong KE: Tracing the
footprints of the breast cancer oncogene BRK-Past till present.
Biochim Biophys Acta. 1856:39–54. 2015.PubMed/NCBI
|
|
12
|
Kang SA, Lee ES, Yoon HY, Randazzo PA and
Lee ST: PTK6 inhibits down-regulation of EGF receptor through
phosphorylation of ARAP1. J Biol Chem. 285:26013–26021. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsui T and Miller WT: Cancer-associated
mutations in breast tumor kinase/PTK6 differentially affect enzyme
activity and substrate recognition. Biochemistry. 54:3173–3182.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harvey AJ and Crompton MR: The Brk protein
tyrosine kinase as a therapeutic target in cancer: Opportunities
and challenges. Anticancer Drugs. 15:107–111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shim HJ, Yang HR, Kim HIe, Kang SA, No KT,
Jung YH and Lee ST: Discovery of
(E)-5-(benzylideneamino)-1H-benzo[d]imidazol-2(3H)-one derivatives
as inhibitors for PTK6. Bioorg Med Chem Lett. 24:4659–4663. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zeng H, Belanger DB, Curran PJ, Shipps GW
Jr, Miao H, Bracken JB, Siddiqui M Arshad, Malkowski M and Wang Y:
Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6
inhibitors. Bioorg Med Chem Lett. 21:5870–5875. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mahmoud KA, Krug M, Wersig T, Slynko I,
Schächtele C, Totzke F, Sippl W and Hilgeroth A: Discovery of
4-anilino α-carbolines as novel Brk inhibitors. Bioorg Med Chem
Lett. 24:1948–1951. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim HIe and Lee ST: An intramolecular
interaction between SH2-kinase linker and kinase domain is
essential for the catalytic activity of protein-tyrosine kinase-6.
J Biol Chem. 280:28973–28980. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kang SA, Cho HS, Yoon JB, Chung IK and Lee
ST: Hsp90 rescues PTK6 from proteasomal degradation in breast
cancer cells. Biochem J. 447:313–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hanke JH, Gardner JP, Dow RL, Changelian
PS, Brissette WH, Weringer EJ, Pollok BA and Connelly PA: Discovery
of a novel, potent and Src family-selective tyrosine kinase
inhibitor. Study of Lck- and FynT-dependent T cell activation. J
Biol Chem. 271:695–701. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arnold LD, Calderwood DJ, Dixon RW,
Johnston ND, Kamens JS, Munschauer R, Rafferty P and Ratnofsky SE:
Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as
potent and selective inhibitors of lck I. Bioorg Med Chem Lett.
10:2167–2170. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu L, Gao Y, Qiu H, Miller WT, Poli V and
Reich NC: Identification of STAT3 as a specific substrate of breast
tumor kinase. Oncogene. 25:4904–4912. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Smal C, Cardoen S, Bertrand L, Delacauw A,
Ferrant A, Van den Berghe G, Van Den Neste E and Bontemps F:
Activation of deoxycytidine kinase by protein kinase inhibitors and
okadaic acid in leukemic cells. Biochem Phamacol. 68:95–103. 2004.
View Article : Google Scholar
|
|
24
|
Summy JM, Trevino JG, Lesslie DP, Baker
CH, Shakespeare WC, Wang Y, Sundaramoorthi R, Metcalf CA III, Keats
JA, Sawyer TK and Gallick GE: AP23846, a novel and highly potent
Src family kinase inhibitor, reduces vascular endothelial growth
factor and interleukin-8 expression in human solid tumor cell lines
and abrogates downstream angiogenic processes. Mol Cancer Ther.
4:1900–1911. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma QL, Yang F, Frautschy SA and Cole GM:
PAK in Alzheimer disease, Huntington disease and X-linked mental
retardation. Cell Logist. 2:117–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bain J, McLauchlan H, Elliott M and Cohen
P: The specificities of protein kinase inhibitors: An update.
Biochem J. 371:199–204. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bain J, Plater L, Elliott M, Shpiro N,
Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR and
Cohen P: The selectivity of protein kinase inhibitors: A further
update. Biochem J. 408:297–315. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Lu Y, Liang K, Hsu JM, Albarracin C,
Mills GB, Hung MC and Fan Z: Brk/PTK6 sustains activated EGFR
signaling through inhibiting EGFR degradation and transactivating
EGFR. Oncogene. 31:4372–4383. 2012. View Article : Google Scholar : PubMed/NCBI
|
